These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34847435)

  • 1. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
    Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
    Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
    Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
    Núñez Y; Garcia-León A; Falgàs A; Serna N; Sánchez-García L; Garrido A; Sierra J; Gallardo A; Unzueta U; Vázquez E; Villaverde A; Mangues R; Casanova I
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
    Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
    Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
    Wu X; Jiao Z; Zhang J; Li F; Li Y
    J Nanobiotechnology; 2023 Apr; 21(1):126. PubMed ID: 37041636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective delivery of T22-PE24-H6 to CXCR4
    Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
    Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
    Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
    EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Dual-Function LipoAraN-E5 Coloaded with
    Wang X; Wang X; Su J; Wang D; Feng W; Wang X; Lu H; Wang A; Liu M; Xia G
    ACS Nano; 2024 Oct; 18(41):27917-27932. PubMed ID: 39364559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines.
    Álamo P; Cedano J; Conchillo-Sole O; Cano-Garrido O; Alba-Castellon L; Serna N; Aviñó A; Carrasco-Diaz LM; Sánchez-Chardi A; Martinez-Torró C; Gallardo A; Cano M; Eritja R; Villaverde A; Mangues R; Vazquez E; Unzueta U
    Acta Biomater; 2021 Aug; 130():211-222. PubMed ID: 34116228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
    Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
    PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
    Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
    Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
    Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
    Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
    Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
    Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
    Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
    Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.